Uncategorized
The American College Of Radiology And The Changing Roles Of Its Members
The role of radiologists is evolving in healthcare due to technological advancements and regulatory changes associated with the Affordable Care Act and health care reform. Read More
Eisai Chief Medical Officer Stewart Geary On Clinical Trial Complexity
Clinical trial costs are increasing, and there’s no clear sign that these increased costs are improving the clinical trials process. Read More
The Opportunities and Challenges for the Chinese Life Sciences Industry
We published an article on the ecosystem for life science innovation in China on MedidataVoice in Forbes this week, and there is plenty more to cover. Read More

“Painful Memories” – How Memory Biases Affect Patient-reported Outcome Measures
People are surprisingly bad at remembering past events, both the factual details and how they were feeling at the time. Read More

Big Pharma, Meet mHealth; mHealth, Meet Big Pharma
Does Moore's Law translate to older, regulated industries such as pharma? Read More

Are Wearables the Next Beepers?
If you think wearable devices are just another tech fad that will go the way of AskJeeves and 3D televisions, think again. Read More

Tech’s Role in Moving Towards Home-based Healthcare
Will technology and data overhaul the healthcare system through increases in home-based patient monitoring? Read More

An Easy Problem to Solve: Speeding Up Payments to Clinical Trial Sites
As with most businesses, a big concern for clinical trial sites is paying the bills. Sites typically receive payments for work performed about four months late while bills are due upfront. Read More

The Promise Of The Digital Health Revolution For Clinical Trials
The global head of research at Sanofi put a policy in place to attach a digital health strategy concept to each molecule that goes through the pharmaceutical company’s pipeline. Read More

PDUFA and the Patient Voice in Drug Development
With the government’s reauthorization of the Prescription Drug User Fee Act in 2012 (PDUFA V), the FDA is trying an experiment to gather patient input by disease group rather than an individual treatment. Read More